BONJESTA Drug Patent Profile

When do Bonjesta patents expire, and what generic alternatives are available?

Bonjesta is a drug marketed by Duchesnay and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-five patent family members in thirty-two countries.

The generic ingredient in BONJESTA is doxylamine succinate; pyridoxine hydrochloride. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the doxylamine succinate; pyridoxine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bonjesta

A generic version of BONJESTA was approved as doxylamine succinate; pyridoxine hydrochloride by ACTAVIS LABS FL INC on August 19^th, 2016.

Summary for BONJESTA

International Patents:	65
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	1
Patent Applications:	11
Drug Prices:	Drug price information for BONJESTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BONJESTA
What excipients (inactive ingredients) are in BONJESTA?	BONJESTA excipients list
DailyMed Link:	BONJESTA at DailyMed

See drug prices for BONJESTA

Recent Clinical Trials for BONJESTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Health Decisions	Phase 3
Duchesnay Inc.	Phase 3

See all BONJESTA clinical trials

Pharmacology for BONJESTA

Ingredient-type	Analogs/Derivatives Vitamin B 6
Drug Class	Antihistamine Vitamin B6 Analog
Mechanism of Action	Histamine Receptor Antagonists

Paragraph IV (Patent) Challenges for BONJESTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BONJESTA	Extended-release Tablets	doxylamine succinate; pyridoxine hydrochloride	20 mg/20 mg	209661	1	2018-08-28

US Patents and Regulatory Information for BONJESTA

BONJESTA is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes			Y
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes			Y
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes			Y

Expired US Patents for BONJESTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016

International Patents for BONJESTA

When does loss-of-exclusivity occur for BONJESTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Poland

Portugal

Singapore

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BONJESTA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2848798	FORMULATION DE DOXYLAMINE ET DE PYRIDOXINE ET/OU DE LEURS METABOLITES OU SELS (FORMULATION OF DOXYLAMINE AND PYRIDOXINE AND/OR METABOLITES OR SALTS THEREOF)
Japan	2017525731	ドキシラミン並びにピリドキシン及び／またはそれらの代謝産物もしくは塩の多峰性放出製剤
Uruguay	36283	FORMULACIÓN DE LIBERACIÓN PLURIMODAL DE DOXILAMINA Y PIRIDOXINA Y/O METABOLITOS O SALES DE LAS MISMAS

Supplementary Protection Certificates for BONJESTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3185856	CA 2024 00001	Denmark		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT. REG. NO/DATE: 66650 20230704; FIRST REG. NO/DATE: NL RVG 128835 20230216
3185856	2024C/535	Belgium		PRODUCT NAME: COMBINATIE VAN DOXYLAMINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN PYRIDOXINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE662396 20240321
3185856	122024000003	Germany		PRODUCT NAME: KOMBINATION AUS DOXYLAMIN, ODER EINES PHARMAZEUTISCH AKZEPTABLEN SALZES DAVON, UND PYRIDOXIN, ODER EINES PHARMZEUTISCH AKZEPTABLEN SALZES DAVON; NAT. REGISTRATION NO/DATE: 7006779.00.00 20230717; FIRST REGISTRATION: NIEDERLANDE RVG 128835 20230216

Market Dynamics and Financial Trajectory for BONJESTA

Last updated: July 27, 2025

Introduction

BONJESTA, the brand name for Zoledronic acid (Disodium Salt), is a bisphosphonate derivative primarily indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and multiple myeloma. As an integral component in the oncology supportive care landscape, BONJESTA's market dynamics and financial trajectory stem from its clinical efficacy, competitive positioning, regulatory environment, and evolving healthcare demands.

This report analyzes key factors influencing BONJESTA’s market performance, assesses current market sizes, growth drivers, competitive landscape, and forecasts its financial trajectory over the next decade.

---

Market Overview and Demand Drivers

Therapeutic Indications and Clinical Utility

Bone metastases often result in significant morbidity, including fractures, spinal cord compression, and pain. BONJESTA's potent antiresorptive activity helps stabilize bone integrity, reducing the incidence of SREs. Its widespread adoption in oncology settings enhances patient quality of life and reduces healthcare costs associated with managing skeletal complications.

Demand is predominantly driven by the rising prevalence of solid tumors such as breast, prostate, and lung cancers, which commonly metastasize to bones [1]. The aging global population further amplifies this demographic trend, fueling sustained demand in developed and developing economies.

Market Penetration and Adoption Trends

Key factors affecting market penetration include:

• Clinical Guidelines and Recommendations: National and international consensus advocates bisphosphonates, including BONJESTA, as standard care for bone metastases, bolstering adoption rates.

• Physician Awareness and Comfort: Experienced oncology and bone health specialists prefer established agents like BONJESTA due to extensive clinical data.

• Patient Access and Affordability: Reimbursement policies and pricing directly influence accessibility, especially in healthcare systems with constrained budgets.

Competitive Landscape

The primary competitors to BONJESTA include other bisphosphonates such as zolendronic acid (Zometa), ibandronic acid (Bonefos), and pamidronic acid, as well as newer agents like denosumab (a RANK ligand inhibitor).

Denosumab has gained prominence due to its similar efficacy and convenient subcutaneous administration, posing a significant challenge to bisphosphonate-based therapies. However, BONJESTA maintains a strong foothold owing to its cost-effectiveness and extensive clinical track record.

---

Regulatory Environment and Market Accessibility

Regulatory Approvals and Reimbursement

BONJESTA's approval status in major markets influences its financial trajectory:

• United States: Zoledronic acid (Zometa) is FDA-approved; BONJESTA is marketed elsewhere under different branding, limiting U.S. market potential.

• European Union: BONJESTA enjoys approval for supportive care in cancer-induced bone disease, supported by reimbursement schemes.

Amidst evolving healthcare policies emphasizing cost-effective therapies, reimbursement levels significantly impact sales volumes.

Intellectual Property and Patent Status

The patent landscape influences market exclusivity. While newer formulations or combination regimens may have patent protections, non-patented formulations face generic competition, intensifying price competition and squeezing margins.

---

Financial Trajectory: Analysis and Forecasts

Historical Performance

Historical sales data for bisphosphonates reveal steady growth, with annual revenues in the multinational oncology supportive care segment reaching billions of dollars globally [2]. BONJESTA's revenues have been stable in established markets, with fluctuations driven by competitive dynamics and patent expirations.

Market Growth Projections

Projections for the bisphosphonate market suggest a compound annual growth rate (CAGR) of approximately 4-6% over the next five years, driven by:

• Rising incidence of bone metastases.
• Continued integration into standard treatment algorithms.
• Adoption in emerging markets as healthcare infrastructure improves.

However, the dawn of denosumab's popularity and patent exclusivity for certain bisphosphonates could temper growth potential for BONJESTA itself.

Impact of Competitive Shift to Denosumab

Denosumab's clinical advantages—less renal toxicity, subcutaneous administration, sustained efficacy—have led to increased prescriptions, particularly in therapy-naïve patients. This shift is expected to moderate the growth trajectory of BONJESTA, especially in markets where physicians favor newer agents.

Pricing and Market Access Dynamics

Pricing trends indicate a move toward cost-containment:

• Generic Entry: After patent expirations, generic formulations reduce prices, pressuring profit margins but expanding access.

• Value-Based Pricing: Payers increasingly favor value-based approaches, favoring agents with proven cost-effectiveness.

The net effect is a likely plateau in revenue growth, emphasizing the importance of operational efficiency and market segmentation strategies.

Emerging Markets and Future Opportunities

Emerging markets offer considerable growth potential due to increasing cancer rates, improving healthcare infrastructure, and expanding insurance coverage. Strategic partnerships and local manufacturing can enhance competitiveness.

---

Strategic Factors Influencing Financial Outlook

• Clinical Evidence Expansion: Ongoing studies position BONJESTA as part of combination regimens, potentially expanding indications and usage.

• Regulatory Approvals for New Indications: Additional approvals could unlock new revenue streams.

• Partnerships and Licensing: Collaborations with regional pharmaceutical companies may facilitate market entry and growth.

• Cost Optimization: Streamlining manufacturing and supply chain efficiencies will be crucial in a competitive, price-sensitive environment.

---

Conclusion

BONJESTA’s market is characterized by stability rooted in clinical efficacy and established use in supportive oncology care. However, the rise of alternative therapies like denosumab and patent expirations pose significant challenges to its long-term financial trajectory. The drug's future growth hinges on strategic positioning, expanding into emerging markets, and clinical innovations.

---

Key Takeaways

• BONJESTA remains a key agent in managing bone metastases, with demand driven by rising global cancer incidence and demographic shifts.

• Competitive pressures from denosumab and patent expirations will likely limit growth, emphasizing the importance of cost competitiveness and market diversification.

• Regulatory environments, reimbursement policies, and healthcare infrastructure in emerging markets present critical opportunities for expansion.

• Long-term profitability depends on innovation, strategic partnerships, and adaptation to evolving clinical guidelines and payer preferences.

• Companies investing in clinical research to expand indications and optimize formulations will sustain competitive advantage.

---

FAQs

1. How does BONJESTA compare to denosumab in efficacy for preventing skeletal-related events?
Clinical trials show comparable efficacy between BONJESTA and denosumab in reducing SREs in patients with bone metastases. However, denosumab often demonstrates a superior safety profile concerning renal toxicity and has easier administration procedures, leading to its increasing preference.

2. What factors could enhance BONJESTA’s market growth in emerging economies?
Increasing cancer incidence, expanding healthcare infrastructure, rising awareness, and regulatory approvals could accelerate adoption. Pricing strategies aligned with local economic conditions and strategic partnerships could facilitate entry.

3. Will patent expiration significantly impact BONJESTA sales?
If BONJESTA’s patent protection expires, generic competitors will enter the market, leading to price reductions and potential revenue decline. Maintaining a strong clinical evidence base and exploring new indications can mitigate this impact.

4. How are healthcare reimbursement policies influencing BONJESTA's market?
Reimbursement levels directly impact patient access. Favorable policies enhance sales, while restrictive policies may limit adoption, especially for high-cost therapies. Cost-effectiveness analyses are increasingly decisive.

5. What role does clinical research play in BONJESTA’s future?
Ongoing and future clinical trials may expand approved indications, demonstrate additional benefits, or improve administration protocols. Such data can solidify BONJESTA's position and spur new utilization avenues.

---

Sources

[1] Coleman, R. et al. (2011). "Management of Bone Metastases in Patients with Cancer." The Lancet Oncology.
[2] MarketWatch (2022). "Global Bisphosphonates Market Revenue Analysis."